241 related articles for article (PubMed ID: 16998297)
1. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection].
Lee MY; Cho H; Kim YM; Lee JS
Korean J Hepatol; 2006 Sep; 12(3):444-8. PubMed ID: 16998297
[TBL] [Abstract][Full Text] [Related]
2. Bell's palsy associated with chronic HCV infection before and during peginterferon alfa and ribavirin therapy.
Jabbari H; Fakharzadeh E; Merat S; Zamini H; Sharifi AH
Arch Iran Med; 2011 May; 14(3):204-5. PubMed ID: 21529112
[TBL] [Abstract][Full Text] [Related]
3. Bell's palsy associated with IFN-alpha and ribavirin therapy for hepatitis C virus infection.
Hoare M; Woodall T; Alexander GJ
J Interferon Cytokine Res; 2005 Mar; 25(3):174-6. PubMed ID: 15767792
[TBL] [Abstract][Full Text] [Related]
4. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
[TBL] [Abstract][Full Text] [Related]
11. Bell's palsy and choreiform movements during peginterferon alpha and ribavirin therapy.
Barut S; Karaer H; Oksuz E; Eken AG; Basak AN
World J Gastroenterol; 2009 Aug; 15(29):3694-6. PubMed ID: 19653353
[TBL] [Abstract][Full Text] [Related]
12. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.
Cauli C; Serra G; Chessa L; Balestrieri C; Scioscia R; Lai ME; Farci P
Haematologica; 2006 Jun; 91(6 Suppl):ECR26. PubMed ID: 16785129
[TBL] [Abstract][Full Text] [Related]
13. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
16. Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir.
Marquez-Azalgara V; Hussaini T; Erb SR; Yoshida EM
Ann Hepatol; 2014; 13(5):565-7. PubMed ID: 25152991
[TBL] [Abstract][Full Text] [Related]
17. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
18. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
19. Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C.
Song JS; Sohn JH; Jeong JY; Min JH; Choi WS; Kim OZ; Pyo JY
Korean J Gastroenterol; 2016 May; 67(5):272-276. PubMed ID: 27206440
[TBL] [Abstract][Full Text] [Related]
20. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
Demirturk N; Aykin N; Demirdal T; Cevik F
Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
[No Abstract] [Full Text] [Related]
[Next] [New Search]